Posts Tagged: "Barash Law"

Over the past 80 years, approximately 40% of all FDA-approved pharmaceutical products have been in the form of pharmaceutical salts. The typical route for claiming such salts in patents involves claim cascades beginning with the ubiquitous “and pharmaceutically acceptable salts thereof” and often ends by naming the salt species of interest. Examples of such salts include sodium or hydrochloride salts…

Over the past 80 years, about 40% of all FDA-approved pharmaceutical products have been in the form of pharmaceutical salts. The typical route for claiming such salts in patents involves claim cascades beginning with the ubiquitous “and pharmaceutically acceptable salts thereof” and often ends by naming the particular salt species of interest. Examples of such salts include sodium or hydrochloride…

In December of 2020, IPWatchdog hosted a webinar discussing the use of and interest in solid-form patents in the pharmaceutical industry. There were many questions during the webinar, and many follow-up inquiries on the “nuts and bolts” of these patents. Issues including prosecution, claim drafting, novelty, obviousness, enablement, non-species claims in a crystalline-form context, claim interpretation and proving infringement. Join…

The solid-state structure of an active pharmaceutical ingredient (API) can profoundly affect its properties.  Consider, for example, drug delivery.  In order for an orally dosed medicament to have biological efficacy, it must release the API in vivo for transport to the target.  If the solubility of the API is too low, there will be insufficient API for efficacy.  If the…